# Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

> **NCT04370483** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Smoldering Plasma Cell Myeloma

## Interventions

- **DRUG:** Leflunomide
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04370483
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-08
- **Primary completion:** 2026-11-10
- **Final completion:** 2026-11-10
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04370483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04370483, "Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04370483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*